Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article reviews systemic lupus erythematosus (SLE) and highlights the FDA approval of belimumab, marking the first new SLE treatment in nearly 50 years, but reports no new clinical trial results.

This study developed a personalized microneedle that delivers finasteride directly to the skin, facilitating a sustained release and potentially reducing side effects associated with oral administration.

This review describes the dermatological uses of the contraceptive ethinylestradiol/chlormadinone acetate for conditions linked to high androgen levels and reports no new clinical results.

This phase I study found that MK-2206 was well tolerated and demonstrated evidence of AKT signaling blockade in patients with advanced solid tumors, with the maximum-tolerated dose established at 60 mg.

This report discusses the FDA's third denial of approval for Aveed, a long-acting testosterone injection by Endo Pharmaceuticals, citing continued safety concerns including severe side effects.

This review covers the use of photobiomodulation devices for hair regrowth in various types of alopecia and reports no new clinical results.

The researchers reported that repurposing the drug eflornithine may offer a treatment option for Bachmann-Bupp Syndrome, highlighting a potential model for other rare diseases.

This study used machine learning to identify molecular predictors of drug response in alopecia areata, suggesting a tool for predicting treatment efficacy based on gene signatures.

This study found that MK-5108 is well tolerated at high doses as monotherapy in cancer patients, showing stable disease and some antitumor activity, particularly in combination with docetaxel.

This article discusses the considerations and challenges surrounding a proposed large-scale trial on testosterone-replacement therapy in older men and reports no new results.

In this study, the authors observed that among elderly participants, 59.1% did not experience depression, correlating with measured average levels of apolipoprotein A and B. They suggest early screening can help manage apolipoprotein levels, potentially reducing depression risk and improving quality of life.

This study concluded that placental mesenchymal stem cells from aborted fetal tissue may serve as an in vitro model for studying spontaneous abortion mechanisms and potential regenerative therapies due to their abnormal gene expression and differentiation capabilities.

This article reviews the use of cyproterone acetate for conditions like prostate cancer and sexual disorders, highlighting its effects on libido but reporting no new specific trial results.

Home photobiomodulation therapy can improve life quality and mobility for disabled individuals.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.

This study found that polymeric micelle formulations significantly improved the targeted delivery of adapalene to hair follicles compared to standard Differin® products, which suggests potential advantages in treating hair follicle-related conditions and reducing side effects.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This summary describes the changes and developments in medical education and accreditation in Australia, as reported by the Australian Medical Council, highlighting increased collaboration among medical schools and new specialty recognitions.

This study demonstrated that novel curcumin analogs CMC2.24, CMC2.23, and CMC2.5 were more effective and less toxic than parent curcumin in inhibiting melanin production in normally pigmented human melanocytes, suggesting potential for skin depigmentation therapies.

This study reports that the Swedish newborn screening program for phenylketonuria, galactosaemia, and biotinidase deficiency is effective, with high sensitivity and specificity, and lower false positive rates compared to other countries, while genetic variants impact detection and incidence patterns in Sweden.

This study found that DNA methylation and histone modification status were altered in peripheral blood mononuclear cells of patients with alopecia areata, suggesting these changes may contribute to the disease's pathological immune responses.

In this phase 1B study, patients with ER-positive/HER2-negative metastatic breast cancer receiving combined pegylated liposomal doxorubicin and pembrolizumab had a disease control rate of 67% with responses lasting a median of 11 months; the treatment was well tolerated and showed potential for extended use.

This study found that PRP injections may safely improve penile curvature and PDQ scores in men with stable-phase Peyronie's Disease, although the curvature reduction observed was not enough to determine long-term clinical significance.

This article covers discussions from the Society of Urologic Oncology Annual Meeting outlining that new therapies, such as Provenge, Prostvac, and denosumab, are making the treatment of advanced prostate cancer more complex but may offer extended survival benefits.

This study found that women with PCOS had higher levels of serum phoenixin isoforms, which correlated with reproductive and metabolic markers, suggesting these isoforms may have a potential diagnostic role.

This study determined that serum AMH levels are higher in women with PCOS compared to controls and may serve as a diagnostic marker for ovarian dysfunction alone or with other tools.

This study evaluates the effectiveness and safety of 2-mg and 4-mg doses of baricitinib in patients with alopecia areata who have lost at least 50% of their scalp hair, comparing outcomes between those with early and late onset of the disease.

In this study, novel substituted benzoyl benzoic acids and phenylacetic acids were potent and selective inhibitors of human steroid 5alpha-reductase type 2, with one compound showing promising bioavailability in rats for potential clinical evaluation.

The researchers reported that a new nanoformulation of paclitaxel-loaded nanoparticles showed superior antitumor effects against malignant melanoma in vitro and in vivo compared to the commercial formulation Taxol^®.

This study found that the addition of SPACE peptide significantly enhanced the penetration of amniotic membrane stem cell metabolites in mice, with only very mild irritation observed.